PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma

Yonsei University

Status and phase

Completed

Phase 2

Conditions

Head Neck Cancer Squamous Cell Metastatic

Head Neck Cancer Squamous Cell Recurrent

Treatments

Drug: PF-00299804

Study type

Interventional

Funder types

Other

Identifiers

NCT01449201

4-2011-0434

Details and patient eligibility

About

Epidermal growth factor receptor (EGFR) is often over-expressed, and have been related to poor prognosis in patients with HNSCC. EGFR targeting strategies showed clinical anti-tumor efficacy in patients with HNSCC. PF-00299804 is a second-generation quinazoline-based irreversible pan-HER inhibitor. In preclinical studies, PF-00299804 has much lower IC50 values than gefitinib in cell lines engineered to express EGFRvIII mutations (1.2 nM versus 2,700 nM) and produces tumor growth inhibition in gefitinib-resistant xenografts. A phase II trial of PF-00299804 in patients with recurrent or metastatic HNSCC is currently ongoing and preliminary report in ASCO 2010 showed its anti-tumor activity against HNSCC. The investigators suggest a phase II trial of pan-HER inhibitor PF-00299804 in patients with recurrent or metastatic HNSCC previously treated with platinum-based chemotherapy.

Enrollment

49 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically confirmed squamous cell carcinoma of head and neck
Age ≥ 18
ECOG PS 0-2
Documented progressive disease after platinum-based systemic chemotherapy (either cisplatin or carboplatin) with or without cetuximab
At least one bidimensionally measurable disease
Adequate organ function for treatment
Availability of tumor tissue for molecular analysis (archival or rebiopsy tissue)

Exclusion criteria

Nasopharyngeal carcinoma
Eligibility for local therapy (surgery or radiotherapy)
Previous treatment with small molecule EGFR tyrosine kinase inhibitors
More than one systemic chemotherapy
Any major operation or irradiation within 4 weeks of baseline disease assessment
Any clinically significant gastrointestinal abnormalities which may impair intake or absorption of the study drug
CNS metastasis with continuous corticosteroid use within 4 weeks of baseline disease assessment
Patients with known interstitial lung disease
Patients with uncontrolled or significant cardiovascular disease (AMI within 12 months, Unstable angina within 6 months, NYHA Class III, IV Congestive heart failure or left ventricular ejection fraction below local institutional lower limit of normal or below 45%, Congenital long QT syndrome, Any significant ventricular arrhythmia, Any uncontrolled second or third degree heart block, Uncontrolled hypertension)
Concomitant malignancy (except adequately treated basal cell cancer of skin or cervical cancer in situ)
Pregnant or breast-feeding women
Other severe acute or chronic medical condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the patient inappropriate for entry into this trial.